Drug intelligence / Profile preview

Meningococcal group A conjugate vaccine

Development stage: Unknown
Lead developer: Serum Institute of India
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Meningococcal group A conjugate vaccine (MCV-A) is a pharmaceutical vaccine designed to prevent meningococcal disease caused by Neisseria meningitidis serogroup A. It functions by inducing an immune response against the capsular polysaccharide of the bacterium. This vaccine is frequently utilized as a control or comparator vaccine in clinical trials evaluating the efficacy and safety of other vaccines, such as typhoid conjugate vaccines, in various populations including children.

Brand names: MenAfriVac
Other names: meningococcal serogroup A conjugate vaccine

Targets

NmA CPS (Neisseria meningitidis group A capsular polysaccharide)TT (Tetanus toxoid)

Beyond the preview

Go deeper on Meningococcal group A conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meningococcal group A conjugate vaccine.

Explore the full profile